About Allogene
Allogene is a publicly listed company based in San Francisco (United States) founded in 2018 by David Chang and Arie Belldegrun. Chimeric antigen receptor cell therapies for cancer treatment are developed. It operates on a HealthTech model. Allogene has raised $531.77 million across 5 funding rounds from investors including Fidelity Investments, Pfizer and TPG. The company has 229 employees. Its chief executive, as recorded, is David Chang. Its website allogene.com draws about 34 thousand monthly visits. Allogene offers products and services including AlloCAR T™, Cemacabtagene Ansegedleucel (Cema-Cel), ALLO-316, and ALLO-329. Its focus areas include Biotechnology and Cell Therapy. Its legal entity is Allogene Therapeutics. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Allogene Therapeutics is engaged in the development of allogeneic CAR T cell therapies targeting blood cancers, solid tumors, and autoimmune diseases. The company is recognized for its innovative AlloCAR T platform, which enables scalable manufacturing and on-demand treatment availability. Research and clinical trials, such as ALPHA3 and RESOLUTION, are conducted to address large B-cell lymphoma and autoimmune conditions. Multiplex gene-engineering and proprietary lymphodepletion technologies are utilized to optimize product efficacy. Partnerships and strategic collaborations are maintained to expand development activities globally.
- Headquarters San Francisco, United States
- Employees 229
- Founders David Chang, Arie Belldegrun
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website allogene.com
- Social LinkedIn
- Legal Name Allogene Therapeutics, Inc.
- Net Profit-$190.89 M (USD)25.9as on Dec 31, 2025
- EBITDA-$194.57 M (USD)20.21as on Dec 31, 2025
- Total Equity Funding$531.77M (USD)
in 5 rounds
- Latest Funding Round$15M (USD), Grant
Apr 2024
- InvestorsFidelity Investments
& 11 more
- Employee Count229
Products & Services of Allogene
Allogene offers a comprehensive portfolio of products and services, including AlloCAR T™, Cemacabtagene Ansegedleucel (Cema-Cel), ALLO-316, and ALLO-329.
Innovative allogeneic CAR T therapy is developed for patients.
Frontline treatment for large B-cell lymphoma is provided.
Therapy for advanced renal cell carcinoma is offered.
Treatment for autoimmune diseases is being developed now.
Funding Insights of Allogene
Allogene has successfully raised a total of $531.77M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $15 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $531.77M
- Total Rounds 5
- Last Round Grant — $15M
- First Round $54,478
(Feb 2016)
- Investors Count 12
All 5 funding rounds of Allogene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $15M | Grant | – | – | |
| Sep 2018 | $120M | Series A | – | Perceptive Advisors, Deerfield | |
| Jun 2018 | $58,340 | Grant | – | – | |
| Apr 2018 | $411.77M | Series A | – | – | |
| Feb 2016 | $54,478 | Grant | – | – |
12 investors in total: 12 institutional.
Investors in Allogene
Allogene has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Pfizer and TPG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Biomedical innovations are transformed into therapies by Vida Ventures. | vidaventures.com | Boston, United States | ||
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
No information is available about Bellco Capital's activities. | bellcocapital.com | |||
Offers asset management and advisory for equities and fixed income portfolios. | 1969 | jennison.com | New York, United States | |
Diversified investment management services are offered in India. | franklintempletonindia.com | Mumbai, India | ||
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Allogene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Allogene
116 people are tracked at Allogene (70 in leadership, 19 in board & advisors, 27 in team); the tracked headcount is 229.
| Name | Role | Group |
|---|---|---|
David Chang | Co-Founder & CEO | Leadership |
Arie Belldegrun | Co-Founder | Leadership |
Nancy Saputra | IT Director, Security | Leadership |
Jeff McLeroy | Vp, Drug Safety & Pharmacovigilance | Leadership |
Kevin H. | Senior Director, Statistical Programming And Infrastructure | Leadership |
Juliette Williams | Associate Director, Program Management | Leadership |
Paul Fisher | Director, Translational Science | Leadership |
Dante Montenegro Jr | Executive Director, R&d Quality | Leadership |
Alex Babayan | Vice President | Leadership |
Judy Seng | Associate Director Clinical Operations | Leadership |
Ibrahim Toorawa | Associate Director, External Manufacturing | Leadership |
Karl Palmares | Associate Director, Fp&a | Leadership |
Charles E. | Senior Director, Supply Chain Business Owner | Leadership |
Spring S. | Director, External Manufacturing & Technology | Leadership |
Farah Fawaz | Senior Vice President | Leadership |
Nancy Liu | Director - Planning, Sourcing, Warehousing | Leadership |
Daniel Hunt | Vp, Corporate & Business Development | Leadership |
Lillian Smith | Vice President, Corporate Counsel | Leadership |
Julie Kang | Associate Director Clinical Operations | Leadership |
Christine Cassiano | Evp, Chief Corporate Affairs & Brand Strategy Officer | Leadership |
96 more people are available in the full profile.
Complete people profiles for Allogene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Allogene
Allogene is a publicly listed company on the NASDAQ with ticker symbol ALLO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Oct 2018
- Listed onNASDAQ: ALLO
- Listed entityAllogene Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS0197701065
- Share price$1.29 (-7.86% on the day) · 2026-10-13
- Market capitalisation$445.7M
- EPS (diluted, trailing year)$-0.67
- Volume (last session)6,543,528
Financials of Allogene
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$190.9M | -$194.6M | |
| 2024 | $22,000 | -$257.6M | -$243.8M |
| 2023 | $95,000 | -$327.3M | -$300.3M |
| 2022 | $156,000 | -$340.4M | -$321.2M |
| 2021 | $114.1M | -$182.1M | -$169.7M |
Detailed financial statements for Allogene
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Allogene
4 dated milestones of Allogene across 8 years, from founding to its latest funding, stage changes and deals.
- Funding First funding round of $54K.
- Founded Allogene is founded.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $15.0M.
Competitors of Allogene
Allogene has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Allogene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Allogene
The website of Allogene (allogene.com) receives about 33.5K visits a month and ranks #1,405,171 among all websites worldwide, #1,819 in Biotechnology and Pharmaceuticals.
- Monthly visits33.5K
▲ 92.2% vs previous month
- Unique visitors8.9K
per month
- Global rank#1,405,171
among all websites
- Category rank#1,819
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit2.1
- Average visit22 sec
- DevicesDesktop 18% · Mobile 82%
Websites whose visitors overlap most with Allogene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| assemblybio.com | 100% | 5.8K | #3,402,677 | View details | |
| mazetx.com | 99% | 9.2K | #2,405,150 | View details | |
| astellasgenetherapies.com | 98% | 1K | View details | ||
| aligos.com | 98% | 3.4K | #3,982,602 | View details | |
| vir.bio | 98% | 29.8K | #1,332,196 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Allogene
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as Allogene (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Allogene
Complete news archive for Allogene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allogene
Allogene was founded in 2018.
Allogene is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
David Chang is the CEO of Allogene, as recorded in our data. They have also founded this company.
Allogene is a funded company, having raised a total of $531.77M across 5 funding rounds to date. The company's 1st funding round was a Grant of $54.48K, raised on Feb 2016.
Allogene has 229 employees.
Allogene Therapeutics is engaged in the development of allogeneic CAR T cell therapies targeting blood cancers, solid tumors, and autoimmune diseases. The company is recognized for its innovative AlloCAR T platform, which enables scalable manufacturing and on-demand treatment availability. Research and clinical trials, such as ALPHA3 and RESOLUTION, are conducted to address large B-cell lymphoma and autoimmune conditions. Multiplex gene-engineering and proprietary lymphodepletion technologies are utilized to optimize product efficacy. Partnerships and strategic collaborations are maintained to expand development activities globally.
Allogene offers AlloCAR T™, Cemacabtagene Ansegedleucel (Cema-Cel), ALLO-316, and ALLO-329.
Yes, Allogene is publicly traded on NASDAQ under the ticker symbol ALLO.
Allogene has 12 investors. Key investors include Fidelity Investments, Pfizer, TPG, Citadel, and European Union.
Allogene operates through Allogene Therapeutics.